Pioneering Safety and Protection in Flu Prevention

DIFF Biotech proudly presents DIFF-flu, China’s first domestically developed live-attenuated influenza vaccine, now in clinical trials. Approved by China’s NMPA as a Class 1.2 innovative vaccine, DIFF-flu combines advanced safety with broad, robust protection.

 

A Novel Attenuation Strategy for Superior Safety

DIFF-flu employs a unique M2 gene-based attenuation technology, setting a new benchmark in influenza prevention. Unlike traditional nasal spray vaccines that rely on cold-adapted strains, DIFF-flu is a replication-restricted vaccine virus, serving as a “safety harness.” This approach achieves the ideal balance of strong attenuation and high immunogenicity.

Figure 1. Schematic Diagram of DIFF-flu's Attenuation Mechanism:The vaccine strain exhibits "limited replication"​ in normal tissues or cells, while maintaining high-efficiency replication in chicken embryos.

Why DIFF-flu Stands Out

• Next-Generation Safety:Uses a unique M2 gene-based attenuation, restricting viral replication in the body while maintaining strong immune response. Ideal for older adults and immunocompromised individuals.
• Triple Immune Defense: Triggers mucosal, cellular, and humoral immunity right at the virus entry point, showing strong protection across past and current strains.
• Accessible for More People:Safer design means nasal spray vaccination is possible for vulnerable populations.
• Scalable and Stable:High-yield production in chicken embryos with a freeze-dried form lasting over a year—ready for global distribution.

 
Meeting Global Trends

 The global vaccination landscape is evolving towards more accessible and convenient preventive care. Following the U.S. FDA’s 2024 authorization for at-home administration of nasal spray influenza vaccines, direct-to-consumer (DTC) models are becoming increasingly viable. With its high safety and stability profile, DIFF-flu is ideally positioned to meet the growing demand for effective, self-administered influenza prevention, unlocking substantial potential in international markets.

DIFF-flu isn’t just a vaccine—it’s a safer, smarter, and more accessible way to protect against influenza.

Figure 2.FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration